Navigation Links
Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia
Date:7/29/2010

significant efficacy in this patient population.

In the current study, total PANSS scores improved in this patient population after ITI-007 administration.  Furthermore, patients who had been randomized to ITI-007 also exhibited improvements in symptoms of depression and sleep.  Although the present study was not powered to demonstrate statistically significant differences in these outcomes, the clinical signals elicited by ITI-007 are encouraging and will be evaluated more fully in future efficacy studies.

A previous study in healthy volunteers demonstrated rapid engagement of target brain receptors with ITI-007 and long-lasting brain residency time using positron emission tomography (PET).  ITI-007 also showed dose-related increases in occupancy of target brain receptors and transporters that are important for antipsychotic and antidepressant efficacy and for enhancing sleep maintenance, such as dopamine D2 receptors, serotonin 5-HT2A receptors, and serotonin transporters.

ABOUT SCHIZOPHRENIA

Schizophrenia is a major neuropsychiatric disorder that affects over one percent of the world population with an illness that begins in late adolescence and lasts a lifetime. Its best known symptoms are "positive symptoms", which include hallucinations and delusions; but other mental functions are also affected, including social and motivational skills ("negative symptoms") and cognitive behaviors, like inattention and poor memory.  Current antipsychotics are effective primarily on reducing positive symptoms but leave negative and cognitive symptoms untouched. Not only are current drugs incompletely effective, but they also have limiting side effects, including troublesome actions on motor function, weight gain, and metabolic symptoms (diabetes and hyperlipidemia), along with sedation, constipation, dizziness, and loss o
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
2. Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
3. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
4. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
5. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
6. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
7. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
8. Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity
9. Reportlinker Adds Personalized Medicine 2010: Assessing the Opportunities and Challenges in Commercializing Companion Diagnostics and Targeted Therapies
10. TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion Therapeutics
11. Drug in New Class of Targeted Therapies Shows Early Promise Against Blood-Related Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... , Aug. 27, 2014 Higher ... insurance are fuelling the demand for medical devices ... rise of medical tourism, the inflow of patients ... The market will continue its steady ascent as ... age-related and non-communicable diseases, compelling significant investments in ...
(Date:8/26/2014)... plc (NYSE: ACT ), a leading global specialty ... and President of Actavis, will provide an overview and update ... Conference 2014 in New York, NY . ... presentation will take place on Tuesday, September 9, 2014 at ... 109 East 42 nd Street, New York, ...
(Date:8/26/2014)... -- Research and Markets  has announced the addition ... report to their offering. Intranasal drug ... administration of drugs for the treatment of local diseases ... and non-allergic rhinitis and sinusitis. The nose is considered ... and systematic drug delivery. Continuous technological ...
Breaking Medicine Technology:Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 2Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 3Frost & Sullivan: Change in Demographics and Surge in Domestic Manufacturing Drive Asia-Pacific Medical Devices Market 4Actavis to Present at Morgan Stanley Global Healthcare Conference 2014 2Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 2Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 3
... 24 Schering-Plough Corporation (NYSE: SGP ... selective adenosine2a receptor antagonist, met the primary endpoint ... suffering from moderate to severe Parkinson,s disease experiencing ... The trial results were presented today at the ...
... , Dear President-Elect Obama:, , ... will start with billions of dollars,earmarked for stem cell research. ... is the voice of the Repair Stem Cell research and,treatment ... federal,funding support for our industry and the medical and scientific ...
Cached Medicine Technology:Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 2Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 4Open Letter to President-Elect Barack Obama From Don Margolis, Chairman and Founder of The Repair Stem Cell Institute 2
(Date:8/27/2014)... August 27, 2014 The Global and ... study on the current state of the Maleic Anhydride ... a basic overview of the industry, including definitions, applications ... domestic market analysis are provided with a focus on ... A comparison between the international and Chinese situation is ...
(Date:8/27/2014)... Australia (PRWEB) August 27, 2014 ... erratic climatic conditions and fluctuations in global supply and ... the past five years. The industry derives a large ... are subject to global market dynamics, with supply and ... Brazil and India. A strong Australian dollar for the ...
(Date:8/27/2014)... August 27, 2014 UNIWIGS, one of the leading ... pieces, offers big deals and sales on all its products, for ... products can save much on UniWigs hair products in ... they can save $10 with a coupon code LABOR10; while when ... coupon code LABOR50. Besides this deal which coupon code is needed ...
(Date:8/27/2014)... Co-operative Research Centre into Microtechnologies, is coordinating ... innovative solutions based on microtechnologies to tackle ... life sciences, among others. IK4-Ikerlan, Ceit-IK4, IK4-Tekniker, ... with CIC microGUNE on this project, which ... Etortek 2013-2014 programme of the Government of ...
(Date:8/27/2014)... 27, 2014 Catalent, the leading ... solutions for drugs, biologics and consumer health products, ... held Australian biomarker research company, Minomic International Limited, ... for prostate cancer therapy. Under the agreement, Catalent ... study with a view to larger scale production ...
Breaking Medicine News(10 mins):Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 2Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 3Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 4Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 5Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:UniWigs Is Offering A Big Sale for Labor Day on All Its Products 2Health News:Microtechnologies for driving forward mobility and human health 2Health News:Catalent and Minomic Collaborate to Bring New Prostate Cancer Treatment to Market 2Health News:Catalent and Minomic Collaborate to Bring New Prostate Cancer Treatment to Market 3
... colleagues from the Institute of Child Health will be studying ... The study will focus on the changes in their brain ... identify and understand the problems in their brain which could ... study is being funded by the Action Medical Research, UK. ...
... grow and currently affects more that 18 million ... need for alternative diabetes therapies with earlier more ... of insulin by the lung may provide an ... alternative insulin delivery systems must meet certain pharmacokinetic ...
... as the Breast Cancer Awareness Month. It is a sad ... and mortality associated with breast cancer//, very few men and ... risk factors and what is to be done in case ... Lauder, founder and president of the Breast Cancer Research Foundation, ...
... Los Angles have taken a major step forward in the ... the development of prostate cancer in animals//. ,The antibody ... and according to Dr. Robert E. Reiter, a professor of ... study's senior author it tells the cancer that it is ...
... known to express endogenous peptide antibiotics called defensins, ... active against bacteria, fungi and viruses//. ... of Nature, describes plectasin-the first defensin to be ... nigrella. Plectasin has primary, secondary and tertiary structures ...
... the deadly HIV/AIDS is accelerating in China with 126,808 ... patients, according to latest health reports//. Experts estimate that ... 80,000 AIDS patients. ,This is considerably higher than the ... over a margin of 19,818. In addition, the patients ...
Cached Medicine News:Health News:New Research To Study Brain Changes In Premature Births 2Health News:HIIP- A Novel Inhaled Insulin Delivery System As An Alternative To Injectable Insulin Therapy 2Health News:Mushroom found to be a source of a new antibiotic: Plectasin 2
... with ease of use make the OM-5 ... Ideal for office or hospital-based urodynamics, the ... cystometry, leak point pressure, or urethral pressure ... make the OM-5 flexible enough to meet ...
Windows-Based Urodynamics for Fast and Straightforward. Testing For Clinics Where Logic and Efficiency are at a Premium...
... The Corkscrew FT II (fully threaded) ... anchor designed to be inserted flush with ... strength and anchor stability. The full thread ... suture anchors with protruding eyelets. Especially advantageous ...
... (fully threaded) is a 5.5 mm diameter ... flush with the cortical bone surface to ... fully threaded design substantially improves pull-out strength ... The fully threaded design prevents anchor pull-back ...
Medicine Products: